About Company

AlphaLife Sciences is an AI-first platform company transforming how novel therapies navigate the complex path from lab to market. Founded in 2020 and headquartered in New Jersey and Singapore, we bridge deep regulatory expertise with AI innovation to solve critical bottlenecks in drug development. Our mission is to streamline the submission lifecycle through the AuroraPrime platform, which powers nonclinical, clinical, CMC, safety, and labeling documentation across the entire drug lifecycle.

By infusing built-in AI agents into life sciences workflows—from data extraction and authoring to quality control, change management and cross-functional review—AuroraPrime delivers compliant, submission-ready regulatory dossiers with unprecedented speed. The platform provides comprehensive eCTD coverage, significantly accelerating critical IND, NDA, BLA, and MAA filings.

Our team combines world-class engineering talent—over 80% from industry leaders such as Google, Microsoft, and Medidata—with deep domain expertise in pharma and regulatory writing. Validated by strategic partners including Microsoft, NVIDIA, Veeva, and Johnson & Johnson, AlphaLife is building the new standard in regulatory automation. Today, the AuroraPrime platform is trusted and adopted by more than half of the top 20 global pharmaceutical companies to deliver enterprise-scale, regulatory-grade impact.

Vision, Mission, and Key Pillar Products

Our Vision is to accelerate global drug development—making it faster and more affordable through AI. Our Mission is to automate life-science content authoring and insight generation with AI, enabling biopharma teams to achieve greater efficiency, quality, and compliance. Our four pillar product lines, in both production and roadmap, are delivered through the AuroraPrime suite—a scalable, hyperscaler-powered GenAI platform built on Content Authoring, Content Insights, an AI Platform for Developers, and 360° Clinical Efficiency—together enabling true end-to-end drug lifecycle transformation.